Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Merck Announces China Approval of Fifth Indication for Keytruda

publication date: Jun 22, 2020

Merck/MSD reported China approval of Keytruda, its anti-PD-1 drug, as a second-line treatment for esophageal squamous cell carcinoma (ESCC). The ESCC must be in patients with locally advanced or metastatic forms of the disease whose tumors express PD-L1. Merck noted that Keytruda is now approved in China for five indications in three different types of cancer, including first-line use in advanced non-small cell lung cancer and second-line treatment for advanced melanoma. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here